Avecho enters final stage of Phase III insomnia trial
Filed with ASX · · 4 pages · English
Summary by 6ix AI
Avecho Biotechnology Limited has announced the recommencement of recruitment for the final stage of its pivotal Phase III clinical trial evaluating its TPM®-enhanced cannabidiol capsule for insomnia. This decision follows a positive interim analysis by the independent Data Monitoring Board, which recommended continuing the trial without increasing the sample size.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Avecho Biotechnology Limited on 6ix
Earlier from Avecho Biotechnology
- Appendix 4D and Half-year Financial Report
- Avecho strengthens BD capability with senior appointment
- Small Holding Share Sale Facility Completion
- Japanese patent granted for CBD capsule
- June 2026 Quarterly Activities Report & Appendix 4C
Later from Avecho Biotechnology
- Avecho to present at the ASX SMIDcaps Conference
- Avecho to present at the Canaccord Drug and Device Confe
- Response to ASX Price Query
- Change of Chief Financial Officer
- September 2026 Quarterly Activities Report & Appendix 4C
Follow Avecho Biotechnology into a list and get an email when it puts out news.
Follow Avecho Biotechnology